Global Viral Vector and Plasmid DNA Market Growth (Status and Outlook) 2023-2029

Global Viral Vector and Plasmid DNA Market Growth (Status and Outlook) 2023-2029

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
LPI (LP Information)' newest research report, the “Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Viral Vector and Plasmid DNA sales in 2022, providing a comprehensive analysis by region and market sector of projected Viral Vector and Plasmid DNA sales for 2023 through 2029. With Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector and Plasmid DNA and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector and Plasmid DNA.
The global Viral Vector and Plasmid DNA market size is projected to grow from US$ 653 million in 2022 to US$ 2342.7 million in 2029; it is expected to grow at a CAGR of 20.0% from 2023 to 2029.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector and Plasmid DNA market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Plasmid DNA
Viral Vector
Segmentation by application
Cancer
Virus Infection
Hereditary Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene

Please note: The report will take approximately 2 business days to prepare and deliver.